Prostate cancer
Conditions
Interventions
Intensity modulated radiation therapy to the prostate bed will be conducted once a day. Prescribed dose will be 54 Gy and 3 Gy per one fraction will be prescribed on 18 consecutive weekdays. The durat
Sponsors
The University of Tokyo
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: a) radiotherapy will be selected as adjuvant or salvage therapy after radical prostatectomy at the University of Tokyo Hospital b) pT3, surgical margin positive, or PSA recurrence after prostatectomy c) ECOG performance status is 0-2 d) written informed consent is gained
Exclusion criteria
Exclusion criteria: a) patient refused to participate in this trial b) distant metastasis is recognized c) past history of irradiation to pelvis d) participation in another clinical trial which may affect this trial e) judged as inappropriate to participation by investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of CTCAE grade 2-4 genitourinary and gastrointestinal toxicity during the initiation of radiotherapy and 90 days from the end of radiotherapy. Toxicities will be graded using CTCAE version 5.0. Biochemical recurrence-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival The incidence of toxicity during the initiation of radiotherapy and 90 days from the end of radiotherapy The incidence of toxicity during the follow-up period after 90 days from the end of radiotherapy Quality of life during the all follow-up period. | — |
Countries
Japan
Contacts
Public ContactHideomi Yamashita
The Univesity of Tokyo Radiology
Outcome results
None listed